Choi, JenniferAnderson, RonaldBlidner, Ada GabrielaCooksley, TimDougan, MichaelGlezerman, IlyaGinex, PamelaGirotra, MonicaGupta, DiptiJohnson, DouglasShannon, Vickie R.Suarez-Almazor, MariaRapoport, Bernardo LeonLacouture, Mario E.2020-10-262020-12Choi, J., Anderson, R., Blidner, A. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer 28, 6119–6128 (2020). https://doi.org/10.1007/s00520-020-05706-4.0941-4355 (print)1433-7339 (online)10.1007/s00520-020-05706-4http://hdl.handle.net/2263/76602Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.en© Springer-Verlag GmbH Germany, part of Springer Nature 2020. The original publication is available at : http://link.springer.com/journal/520.Bullous dermatosesCorticosteroidsCutaneous IrAEsInflammatory dermatitisPruritusSkin rashVitiligoImmune checkpoint inhibitor (ICI)Immune-related adverse events (IrAEs)Postprint Article